HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up

Journal of the American Academy of Dermatology

Volumn 74, Issue 2, 2016, Pages 374-375

  Talamonti, Marina ^a   Galluzzo, Marco ^a   Chimenti, Sergio ^a   Costanzo, Antonio ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MARKER; USTEKINUMAB; BIOLOGICAL MARKER; DERMATOLOGICAL AGENT; HLA C ANTIGEN; HLA-C*06 ANTIGEN;

ADULT; ALLELE; ARTICLE; BODY MASS; CAUCASIAN; DISEASE DURATION; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RETROSPECTIVE STUDY; AGED; GENETICS; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADULT; AGED; ALLELES; BIOMARKERS; DERMATOLOGIC AGENTS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HLA-C ANTIGENS; HUMANS; MALE; MIDDLE AGED; PSORIASIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; USTEKINUMAB; YOUNG ADULT;

EID: 84973411944     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2015.08.055     Document Type: Article

References (5)

1. 1 Prieto-Pérez, R., Cabaleiro, T., Daudén, E., Ochoa, D., Roman, M., Abad-Santos, F., Genetics of psoriasis and pharmacogenetics of biological drugs. Autoimmune Dis, 2013, 2013, 613086.
2. 2 Tejasvi, T., Stuart, P.E., Chandran, V., et al. TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol 132 (2012), 593–600.
3. 3 Vasilopoulos, Y., Manolika, M., Zafiriou, E., et al. Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population. Mol Diagn Ther 16 (2012), 29–34.
4. 4 Schmitt-Egenolf, M., Eiermann, T.H., Boehncke, W.H., Ständer, M., Sterry, W., Familial juvenile onset psoriasis is associated with the human leukocyte antigen (HLA) class I side of the extended haplotype Cw6-B57-DRB1*0701-DQA1*0201 DQB1*0303: a population- and family-based study. J Invest Dermatol 106 (1996), 711–714.
5. 5 Talamonti, M., Botti, E., Galluzzo, M., et al. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol 169 (2013), 458–463.